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Abstract 
Background: Malaria infections during pregnancy lead to sequestration of parasite infected red blood cells in the 
placenta. Placental infection can result in adverse outcomes for mothers and infants. Despite many studies, it remains 
unclear which peripheral blood infections during pregnancy lead to development of placental malaria. Understand‑
ing the timing of peripheral infections that lead to placental malaria and the ability of intermittent preventive treat‑
ment with sulfadoxine–pyrimethamine (SP‑IPT) and artemisinin‑based combination therapy to clear infections will 
enable the rational design of new interventions to decrease the burden of malaria in pregnancy.
Methods: Microsatellite markers were used to genotype peripheral and placental malaria infections in an observa‑
tional cohort in Blantyre, Malawi. Genotypes were compared to determine the timing of infections that sequester 
in the placenta. The effects of SP‑IPT and artemether–lumefantrine as curative treatment were also evaluated by 
assessing the occurrence of peripheral infections or matching genotypes between peripheral and placental parasites 
following treatment.
Results: Genotypes from 92 peripheral samples prior to delivery, 26 peripheral samples at delivery, and 29 placental 
samples were compared. Thirty percent of women with genotyped parasites in their placentas that had peripheral 
infections detected during pregnancy had matching peripheral‑placental genotypes. Matching genotypes were not 
associated with gestational age and occurred from 13 to 39 weeks. Among women with more than one genotyped 
peripheral infection during pregnancy, 80 % had persistent infection with the same genotype while the remaining 
were new infections. Among infections treated with SP or artemether–lumefantrine, 28/84 (33 %) and 9/56 (16 %) 
had infection detected after treatment, respectively. Recrudescent infections were detected after both treatments 
and occurred up to 76 days after treatment. Women treated with SP‑IPT and artemether–lumefantrine had genotypes 
matching treated infections detected in the placenta.
Conclusions: Placental malaria can occur at any time during pregnancy. In the context of late enrollment in antena‑
tal care, interventions that protect all women of childbearing age and throughout pregnancy are needed. Currently 
used medications do not always clear peripheral or placental infections. The ability of anti‑malarial drugs to prevent or 
clear placental infections should be considered in the development of future interventions.
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Background
Malaria infection during pregnancy is a major public 
health concern in sub-Saharan Africa, where it is esti-
mated to result in 100,000 infant deaths [1]. The adverse 
effects of malaria during pregnancy are due to seques-
tration of parasite-infected red blood cells in the pla-
centa. Placental sequestration is mediated by parasite 
expression of a pregnancy specific variant surface anti-
gen (VAR2CSA) on the red blood cell surface. Parasites 
from infections in all trimesters express VAR2CSA and 
are capable of binding to the placental target chondroi-
tin sulfate A [2]. Women, especially in their first and 
second pregnancies, are particularly vulnerable because 
they have not acquired immunity to parasites expressing 
VAR2CSA [3]. Placental malaria infection is estimated to 
cause 900,000 low birth weight deliveries annually in sub-
Saharan Africa through both intrauterine growth retar-
dation and preterm delivery [4].
Previous studies have compared parasites detected 
at the time of delivery in the peripheral or cord blood 
to parasites detected in the placenta. While some stud-
ies have suggested that only a subset of peripheral infec-
tions sequester in the placenta, others have shown a large 
overlap between parasites found in each of these com-
partments [5–9]. Only one prior study has compared 
the parasite genotypes found in the maternal peripheral 
blood throughout pregnancy to the genotypes detected 
in the placenta. In that study, which was conducted in 
an area of seasonal, low malaria transmission, half of the 
women had placental genotypes detected in the periph-
ery at some point prior to delivery and half of women 
had novel genotype(s) in the placenta. Treatment did not 
decrease the likelihood of finding matching genotypes in 
the periphery and in the placenta, suggesting that treat-
ment may not always clear parasites from the periphery 
or the placenta [10].
Current recommendations to prevent malaria during 
pregnancy include intermittent preventive treatment 
with sulfadoxine–pyrimethamine (SP-IPT) after the first 
trimester, use of insecticide treated bed nets, and prompt 
and effective case management. The efficacy of these 
interventions is limited by behavioural factors, such as 
the timing of enrollment in antenatal care, and biologi-
cal factors, such as the development of anti-malarial drug 
resistance. Women in sub-Saharan Africa often enroll 
in antenatal care and initiate SP-IPT late in the second 
or early in the third trimester when infection may have 
already occurred. Additionally, the spread of resistance to 
SP, especially in East Africa, threatens the efficacy of this 
strategy. Determining the timing of peripheral infections 
that lead to placental sequestration and the ability of 
treatment during pregnancy to clear the placenta could 
inform the development of more effective interventions 
decrease the burden of malaria in pregancy.
An observational cohort study in Blantyre, Malawi pro-
vided an opportunity to conduct a longitudinal exami-
nation of peripheral infections during pregnancy and 
compare them to placental infections. Parasite genotypes 
in the periphery detected throughout pregnancy were 
compared to each other and to genotypes found in the 
placenta in order to describe parasite dynamics during 
pregnancy. Determining the timing of peripheral infec-
tion leading to placental sequestration is challenging. In 
this study the timing of potential placental infection is 
inferred based on the gestational age at the first periph-
eral occurrence of a genotype detected in the placenta. 
While this method may be indirect, direct evidence of 
timing is limited by the fact that it is not feasible to sam-
ple the placenta at the time of peripheral infection prior 
to delivery. Parasites may not sequester immediately, but 
may subsequently alter their var gene expression and 
become capable of adhesion. Regardless of exact timing 
of sequestration, understanding the timing of infection 
with the potential for sequestration is critical to tailor-
ing interventions. Because not all parasites are likely to 
express VAR2CSA, the hypothesis of this study is that 
only a subset of peripheral parasites would sequester in 
the placenta. Similarly, because women may encounter 
this subset of parasites at any time, peripheral infections 
at any time throughout pregnancy could lead to placen-
tal infection. This study also assessed the effects of SP as 
IPT and artemether–lumefantrine as curative treatment 
on peripheral infection. The effectiveness of these treat-
ments in clearing the placenta was inferred by comparing 
the genotypes of parasites found at the time of treatment 
to those found in the placenta.
Methods
Study population
Four-hundred and fifty pregnant women were enrolled 
in an observational cohort study of malaria during preg-
nancy in Blantyre, Malawi between June 2009 and June 
2010. All women were in their first or second pregnancy 
and were less than or equal to 28 weeks gestational age 
based on clinical assessment at enrollment. Women were 
followed monthly during pregnancy and encouraged 
to come to the clinic if they had intercurrent illness. At 
each encounter, peripheral blood smears and dried blood 
spots on filter paper were collected. At delivery, these 
same specimens and placental blood and tissue sam-
ples were collected. After quickening, women received 
SP-IPT up to three times separated by at least 4 weeks. 
Women with malaria detectable by blood smear at rou-
tine or sick visits were treated for malaria in accordance 
Page 3 of 8Cohee et al. Malar J  (2016) 15:483 
with the national guidelines: quinine in the first trimes-
ter and artemether–lumefantrine (AL) in the second and 
third trimesters. Early in the study a few smear positive 
women received SP-IPT as scheduled because they were 
asymptomatic. Molecular detection of infection was 
done after the study was complete and was not available 
for clinical care of the study participants. Details of the 
study design and results have been described previously 
[11]. Written informed consent was obtained from all 
participants. The study protocol and informed consent 
document were approved by the University of Malawi 
College of Medicine Research and Ethics Committee and 
the University of Maryland Institutional Review Board.
Laboratory procedures
Procedures for specimen collection, placental biopsies, 
and microscopy were performed as described in Kalilani-
Phiri et al. [11].
Molecular detection
DNA was extracted from frozen placental samples and 
dried blood spots of peripheral blood and placental blood 
using the Qiagen QIAamp® 96 DNA Blood kit (Valen-
cia, CA, USA). Quantitative real time polymerase chain 
reaction (qPCR) was used to detect the gene for Plas-
modium falciparum lactate dehydrogenase. PCR master 
mix, primers and probes were purchased from Applied 
Biosystems (Foster City, CA, USA). Twenty-five micro-
litre reactions containing 1 μl extracted DNA were run. 
Extraction and qPCR protocols are described in detail on 
the University of Maryland website [12].
Placenta evaluation
Placental malaria was defined as the presence of haemo-
zoin pigment or parasites by histology or molecular 
evidence of infection using qPCR. Peripheral blood infec-
tions were categorized as either microscopic (smear 
positive, confirmed by qPCR) or submicroscopic (smear 
negative, but qPCR positive).
Genotyping
All placental samples with parasites detected by qPCR 
underwent genotyping. Peripheral samples from any 
woman who had either placental infection and  ≥1 
peripheral infection or no placental infection and  ≥2 
peripheral infections were genotyped. Genotypes were 
based on six of the twelve unlinked microsatellite mark-
ers described in Anderson et  al. [13]. Prior work dem-
onstrated that these markers (Polyα, PfPK2, TA81, Ara2, 
TA87, and TA40) were sufficient to describe genetic 
diversity and relatedness among parasites in this specific 
population [14]. Product sizes of hemi-nested PCR reac-
tions were resolved by capillary electrophoresis. Output 
files were analysed using Genemapper 4.0 (Applied Bio-
systems, Foster City CA, USA) with default microsatel-
lite analyses settings. Genomic control strains: 3D7, 
HB3, and V1S (ATCC-MR4, Manassas VA, USA) were 
included to determine the characteristic morphology of 
peaks for each marker and to control for slight variations 
in capillary electrophoresis. Only peaks with the charac-
teristic morphology above the threshold of two times the 
relative fluorescent units of background peaks in nega-
tive controls were scored. Fragment size was determined 
by manual inspection of each electropherogram and 
normalized against the 3D7 control. The adjusted peak 
sizes were rounded to the nearest nucleotide repeat size 
using a custom Perl script. Samples were analysed once 
the data had been adjusted and binned. Primers used in 
this study, as well as, microsatellite genotyping and scor-
ing protocols are described in detail on the University of 
Maryland website [12].
Data analysis
Samples with three or more detected microsatellite 
markers were considered evaluable. Genotypes were con-
sidered to match if identical alleles were detected in at 
least 4/6, 3/5, 3/4, or 2/3 of loci. The absence of match-
ing of one allele at some loci was allowed because, with 
polyclonal infections, alleles may occasionally be unde-
tectable [15]. Multiplicity of infection (MOI) was defined 
as the highest number of alleles found at a single locus 
in an infection and represents the number of simultane-
ous infections carried in a patient. Because of small num-
bers of peripheral samples from the time of delivery with 
infection, MOI was calculated with all peripheral samples 
prior to and at delivery.
Peripheral infections through pregnancy were classified 
as chronic, if matching genotypes were detected and new, 
if genotypes did not match. When assessing the ability of 
treatment to clear infections, infections were classified 
as recrudescent, if matching genotypes were detected, 
or new, if genotypes did not match. Gestational age at 
enrollment was calculated based on the last menstrual 
period or by the fundal height if the last menstrual period 
was not known.
Data analysis was performed using STATA version 
12.1 software (Stata Corp, College Station, TX, USA). 
Student’s t-tests or Wilcoxon rank-sum were used for 
comparisons of normal and non-normal distributions 
of continuous variables, respectively. Chi-squared and 
Fisher’s exact tests were used for comparisons of propor-
tions. For time to infection following treatment analysis, 
the log-rank test was used for univariate, categorical pre-
dictors and Cox proportional hazard regression was used 
for univariate analysis of continuous predictors and mul-
tivariable models. Predictors with p < 0.2 were included 
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in model and interactions were evaluated. Statistical sig-
nificance was set at p < 0.05.
Results
All available peripheral blood (N =  2681) and placental 
(N = 317) samples from the 450 women enrolled in the 
study were screened for molecular evidence of infection 
[16]. Among the placental samples, 72 had molecular evi-
dence of infection and evaluable genotypes were obtained 
from 29 (40  %). Genotyping was more likely to be suc-
cessful in placentas with active infection detected by his-
tology compared to placental parasites detected only by 
PCR (p = 0.008). Obtaining evaluable genotypes was also 
associated with higher concentrations of parasite DNA. 
Sixty-six percent of samples with DNA concentrations 
above the median able to be genotyped but only 24 % of 
samples equal to or below the median (p  =  0.001). No 
evidence of a PCR inhibitor was detected.
One hundred ten peripheral samples from prior to 
delivery were genotyped either from women with evalu-
able placental genotypes or from women with more 
than one peripheral infection detected during preg-
nancy. Evaluable genotypes were obtained from 92 (84 %) 
peripheral infections.
Peripheral samples from the time of delivery were also 
genotyped if a placental genotype was available. Three 
women with placental genotypes available did not have a 
peripheral sample from delivery. Seven (27 %) of the 26 
available samples had infection detected and all were able 
to be genotyped.
Lower multiplicity of infection in the placenta compared 
to the periphery
Seventy-seven percent of peripheral infections were 
polyclonal. The mean MOI of peripheral infection was 
3.5 (range 1–10). Two-thirds of placentas had polyclonal 
infections. The mean placental MOI was significantly 
lower than the MOI of peripheral samples [2.1 (range 
1–4) p  <  0.001]. There is no change in these results if 
peripheral samples from the time of delivery are removed 
from the analysis.
Timing of peripheral infections associated with placental 
sequestration
Timing of peripheral infections associated with the pres-
ence of placental sequestration was assessed by matching 
parasite genotypes between peripheral infections pla-
centa. Among 29 women with genotyped placental infec-
tions, sixteen (55 %) had at least one peripheral infection 
detected during pregnancy. These 16 women had 43 
episodes of infection (Fig.  1a). One-third of women 
(6/16, 38  %) had placental parasite genotypes detected 
in the periphery prior to delivery that were identical 
to the parasites found in the placenta. Initial detec-
tion of a placental genotype in the periphery occurred 
at a range of gestational ages (13, 17, 27, 28, 33, and 
39 weeks) (Fig. 1b). Five out of six of these women had 
placental genotypes present in the periphery in multiple 
specimens.
Peripheral infections detected at delivery are more likely 
to share a placental genotype than peripheral infections 
earlier in pregnancy
Among women with genotyped placentas, the proportion 
of peripheral samples with infection prior to and at deliv-
ery was similar (20 vs 27 %, p = 0.44). At delivery, periph-
eral infections commonly matched the placental infection 
(5/7, 71 %). Whereas, less than one-third (13/43, 30 %) of 
peripheral infections prior to delivery contained the pla-
cental genotype (p = 0.08).
Dynamics of infections in the periphery during pregnancy
Twenty-seven women had evaluable genotypes from 
at least two peripheral infections during pregnancy. 
Twenty-two women (81  %) had at least one pair of 
matching peripheral genotypes (Fig.  2). Among women 
with more than one genotyped peripheral infection dur-
ing pregnancy: 22 had chronic infections and five had 
new infections. Women with chronic infections were 
not different from women with new infections in terms 
of age, gravidity, gestational age at enrollment, number of 
visits, or placental malaria status (Table 1).
When pairs of infections were compared, the initial 
infection of the pair occurred at later gestational ages 
when the subsequent infection was chronic as compared 
to new (23 vs 19 weeks, p = 0.05). There was no differ-
ence between the duration of time between the two sam-
ples. Administration of SP-IPT or AL between the two 
infections was not associated with having chronic or new 
infection (Table 2).
Effects of SP‑IPT and artemether–lumefantrine on parasite 
clearance from the periphery and the placenta
Among infections for which women received SP-IPT or 
treatment with AL, 28/84 (33  %) and 9/56 (16  %) had 
subsequent infections, respectively. Treatment with AL 
decreased the rate of subsequent infection by 55 % when 
compared to SP (CI 5–80  %, p  =  0.03) (Fig.  3). Gesta-
tional age at the time of initial infection, bed net use at 
the time of initial infection, and placental malaria were 
not associated with subsequent infection. Recrudescent 
infections were detected following both medications 
(Table  3). Recrudescence occurred up to 76  days after 
treatment.
Figure  1b depicts the peripheral and placental geno-
types from women treated with SP only or AL in addition 
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to SP. Both groups have genotypes from treated infections 
detected in the placenta. For example, subject #4 received 
3 doses of SP and no other anti-malarial medication. She 
had peripheral infection at 13 and 36  weeks gestational 
age with parasites of the same genotype as was detected 
in her placenta. Subjects #2 and #3 had microscopically 
detected infections that were treated with AL and match-
ing genotypes from these peripheral infections were 
detected in their placentas. This implies that neither SP 
nor AL cleared the placenta of these genotypes or, alter-
natively, that neither drug cleared these genotypes from 
the periphery and they later sequestered in the placenta.
Discussion
These data suggest there is no clear pattern of timing 
of peripheral infections resulting in placental infec-
tion, supporting the hypothesis that women are at risk 
Fig. 1 Comparison of placental and peripheral parasite genotypes. a Flow diagram of peripheral infections in women whose placentas were geno‑
typed. b Infection and treatment history of women with matching peripheral and placental genotypes
Women with ≥2 
genotyped samples 
(N=27)




Women with chronic 
(matching)    
peripheral infecons 
(N=22)
104 pairs of infecons
75 matching  
pairs
Fig. 2 Flow diagram of peripheral infections in women with at least 
two infections during pregnancy
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of developing placental infection throughout pregnancy. 
Additionally, neither SP-IPT nor AL completely clears 
peripheral or placental infections. These findings have 
implications for the development of interventions to fur-
ther decrease the burden of malaria during pregnancy.
Lower MOI in the placenta compared to peripheral 
samples and a 30  % concordance rate between para-
sites from the periphery and the placenta, suggest that 
not all peripheral infections lead to placental sequestra-
tion. While these results may be biased based on limita-
tions of genotyping placental samples, the results have a 
strong pathophysiological basis. Placental sequestration 
of some peripheral infections may be limited because of 
either lack of variant surface antigen expression that can 
cause placental sequestration or the ability of AL or SP-
IPT to clear some of these infections. Parasites infecting 
both the peripheral blood at delivery and the placenta 
have been shown to preferentially express VAR2CSA 
and in in  vitro analyses have shown that parasites have 
the capacity to adhere to the placenta early in pregnancy 
[2]. Sequestration has also been shown to be influenced 
by maternal antibody responses to parasite pregnancy 
specific surface antigens [10]. This suggests that interven-
tions that target parasites that sequester in the placenta, 
such as a VAR2CSA vaccine, may decrease placental 
infection, but may still allow for peripheral infection dur-
ing pregnancy.
Women are vulnerable to placental infection through-
out pregnancy. Thus, interventions that target a sin-
gle period of pregnancy are unlikely to be successful in 
decreasing placental malaria. In this study, placental 
genotypes were found in the peripheral blood through-
out pregnancy, without a consistent pattern. These data 
suggest that women acquire peripheral infections that 
Table 1 Characteristics of women with chronic infections compared to new infections during pregnancy






Mean age in years (95 % CI) 19.0 (17.7–20.3) 20.2 (16.4–24.0) 0.5
Primigravid (%) 82 60 0.3
Mean gestational age in weeks at enrollment (95 % CI) 18 (16–20) 16 (11–22) 0.5
Mean number of visits (95 % CI) 7.8 (6.7–8.9) 7.0 (4.0–10.0) 0.5
Had any placental malaria (%) 100a 75 0.2






Gestational age in weeks at initial infection detection (95 % CI) 23 (19–28) 19 (15–24) 0.05
Days between samples (95 % CI) 46 (28–63) 74 (50–98) 0.08
SP‑IPT between samples administered (%) 28 17 0.3
Artemether–lumefantrine between samples (%) 13 3 0.2
Fig. 3 Peripheral infection following treatment with SP‑IPT or 
artemether–lumefantrine. Kaplan–Meier curve of time to subsequent 
infection by treatment. Patterns of peripheral infection following 
treatment
Table 3 Ability of  SP-IPT and  AL to  clear infections dur-
ing pregnancy




Any subsequent infection 28 (33) 9 (16)
Recrudescent infection (%) 13 (15) 7 (13)
New infection (%) 5 (6) 1 (2)
Type not able to be determined (%) 10 (12) 1 (2)
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eventually sequester in the placentas at all stages of preg-
nancy. More direct evidence could be provided by deter-
mining the VAR2CSA expression patterns and placental 
binding capability of initial peripheral infections. Future 
studies should consider these methods.
In the current study placental genotypes were more 
similar to peripheral genotypes at the time of delivery 
than to peripheral genotypes detected earlier in preg-
nancy. There are several possible explanations for the 
similarity of genotypes in the placenta and in the periph-
ery at delivery: peripheral infection with parasites that 
sequestered in the placenta early in pregnancy have 
resolved by the time of delivery; new peripheral infec-
tions occurred late in gestation and infected erythrocytes 
sequestered in the placenta just before delivery; parasites 
previously sequestered in the placenta may be released 
into the periphery in response to the stress of labour; 
placental samples may be contaminated with maternal 
peripheral blood leading to an overrepresentation of 
matching genotypes between these two compartments. 
Regardless of the explanation, this highlights the impor-
tance of comparing infections from throughout preg-
nancy with placental infections at the time of delivery to 
further understand the dynamics of infection during this 
vulnerable period.
Of the six women with matching genotypes detected 
in the periphery and in the placenta, three had received 
SP only or artemether–lumefantrine in addition to SP 
suggesting that neither drug effectively clears either the 
periphery or the placenta. This is further supported by 
the finding that following treatment with either SP or 
AL, 14 % of women had recrudescence detected prior to 
delivery. While resistance to SP may explain the high rate 
of recrudescence following IPT, the high rate of recru-
descence after treatment with AL is unanticipated. One 
explanation is that some anti-malarial drugs may not 
achieve therapeutic levels in the placenta. Thus, parasites 
sequestered in the placenta are protected and intermit-
tently released into the peripheral blood. Parasites that 
evade clearance by sequestration in the placenta may 
have longer exposure to and thus greater chance of devel-
oping resistance to artemisinin partner drugs.
There are several important limitations to this study. 
Not all placental samples were successfully genotyped. 
Genotyping failures were due to low concentrations of 
parasite DNA in the placenta. It is unlikely that these 
technical challenges led to a bias in these results. Because 
of late enrollment in antenatal care, limited data from the 
first trimester is available. Infections present at enroll-
ment, which are more common than after enrollment, 
likely represent the cumulative exposure during the first 
trimester and placental genotypes that do not match 
peripheral genotypes detected during follow-up may 
have been acquired prior to enrollment in antenatal care 
[11].
This study has several implications for the development 
of interventions to decrease the burden of malaria during 
pregnancy. If peripheral infections that lead to placental 
sequestration can occur at any time during pregnancy, 
then interventions to prevent or treat all infections dur-
ing pregnancy are essential to protect the health of both 
mothers and their newborns. Interventions could target 
all women of childbearing age to prevent malaria infec-
tions during pregnancy. Anti-malarials that prevent or 
treat established infections in the placenta are needed. 
Given that neither SP-IPT nor AL appear to completely 
clear the placenta or the periphery of established infec-
tion, either new treatments that do clear the placenta 
or interventions to prevent all malaria infections dur-
ing pregnancy are critical. Trials evaluating anti-malar-
ial drugs for use during pregnancy need to monitor for 
recrudescence longer than the standard 28 or 42  days 
and include placental genotyping to evaluate the ability of 
drugs to clear the placenta.
Conclusions
Placental malaria can occur at any time during preg-
nancy. Once infection is established in the placenta, cur-
rently available medications may not reliably clear the 
infection. In the context of late enrollment in antenatal 
care, interventions that protect all women of child bear-
ing age and throughout pregnancy are needed. The ability 
of anti-malarial drugs to prevent or clear placental and 
peripheral infections should be considered in the devel-
opment of future interventions.
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